Meeting
2022 ASCO Genitourinary Cancers Symposium
Survival of patients with metastatic prostate cancer and comorbid obesity.
Authors
Nina Cheranda
Saint Louis University, St. Louis, MO
Nina Cheranda , Suhong Luo , Forest Riekhof , Srinivas Govindan , Kristen Marie Sanfilippo , Martin W. Schoen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 116)
DOI
10.1200/JCO.2022.40.6_suppl.116
Abstract #
116
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer.
First Author: Neal D. Shore
Poster
2020 ASCO Virtual Scientific Program
TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).
First Author: Samuel R. Denmeade
Poster
2023 ASCO Annual Meeting
Associations between androgen-directed treatments and AR mutational landscapes in the circulating tumor DNA of a real-world metastatic prostate cancer cohort.
First Author: Elisa M. Ledet
Poster
2023 ASCO Annual Meeting
mFAST-SeqS based aneuploidy score in circulating cell-free DNA and role as early response marker in patients with metastatic prostate cancer treated with androgen receptor signaling inhibitor.
First Author: Khrystany T. Isebia